FOR IMMEDIATE RELEASE 5/14/21 STATEMENT FROM NCODA’s Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org LEGISLATIVE VICTORIES FOR ONCOLOGY PATIENTS IN ALABAMA & OKLAHOMA The NCODA Legislative & Policy Advisory Committee wants to commend the Oklahoma Legislature and Governor Kevin Stitt for signing […]

May 12, 2021 Texas Oncology’s leaders and physicians serve patients and their families in many ways – including those that lead them to the floor of the Texas State Capitol in Austin. Recently, Steven R. Paulson, M.D., president and chairman of the board, Texas Oncology; Kathryn Hudson, M.D., hematologist and medical oncologist at Texas Oncology–Austin […]

The PAN Foundation is a national organization dedicated to helping federally and commercially insured people living with life-threatening, chronic, and rare diseases with the out-of-pocket costs for their prescribed medications. Learn more about certain patient assistance funds below. Chronic Lymphocytic Leukemia The PAN Foundation’s chronic lymphocytic leukemia (CLL) patient assistance fund provides a 12- month grant […]

Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer April 27, 2021 – Prescription Drug User Fee Act (PDUFA) Target Action Date Set for October 26, 2021 Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that that the U.S. […]

For Immediate Release: April 22, 2021 Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that […]

FOR IMMEDIATE RELEASE April 26, 2021    NCODA Welcomes New Executive Council Member Cazenovia, NY – NCODA, Inc. is pleased to announce our expanded leadership to the Executive Council. Lucius Daniel, PharmD, the Lead Clinical Pharmacy Specialist with Karmanos Specialty Pharmacy in Troy, Michigan, has joined the Executive Council as of April 2021. Lucius has […]

FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma Sarclisa regimen reduced risk of disease progression or death by 45% compared to standard of care in patients who had relapsed after one to three prior therapies While the median progression free survival (PFS) for Sarclisa combination therapy […]

– FOTIVDA is the First Therapy Approved for Adults with Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies – – AVEO ACE Patient Support Program in Place to Assist with Access, Affordability, and Treatment Adherence – March 22, 2021 07:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq: AVEO) today announced […]

SANTA MONICA, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The approval makes Yescarta the first chimeric […]

March 1, 2021 —U.S. Commercial Launch Underway— WALTHAM — March 1, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in […]

FOR IMMEDIATE RELEASE February 23, 2021 STATEMENT FROM – NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org ANY WILLING PROVIDER – STILL A MAJOR ISSUE IN ONCOLOGY As we begin to navigate 2021, it is important for the oncology community to speak […]

FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50% Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics frequently underrepresented in advanced NSCLC trials This is the third approval for Libtayo in the U.S. […]